Baird cuts Ultragenyx Pharma to Neutral, trims price target
Baird downgraded Ultragenyx Pharma to Neutral and cut its price target to $16.00 per share from $40.00, according to ratings actions
Ratings actions GMT) Ultragenyx Pharma Price Target Cut to $16.00/Share From $40.00 by BairdRatings actions